In the first half of 2014, Zentiva had a turnover of RON200.13 million and a net profit of RON27.18 million.
The pharmaceutical company’s operating revenue increased 13%, to RON230.2 million but not enough to make up for a 21% rise in operating expenses , which reached RON206 million, Zentiva said in its earnings report released Wednesday.
Costs for raw materials and expendables grew by nearly one third, from RON100 million in the first half of 2014 top RON131.3 million in the first half of this year.
Zentiva’s finite product stocks grew to RON17.54 million in the first half from RON938,000 in the same period last year.